San Carlos, CA. - May 18, 2022 - Regencor, Inc., a
leading pre-clinical company in cardiac regeneration, announced today the appointment of
as President and CEO. Former CEO and co-founder Tom Okarma will remain with the company as
Executive Chairman and
continue his involvement with daily operations.
Through 20 years of experience as an executive and lawyer, Mr. Edwards has helped businesses and clients navigate sophisticated strategic, legal, and regulatory issues. Working with both public and private companies, Mr. Edwards has expertise in growing business enterprises and successfully building shareholder value.
“We are delighted to welcome Sean to Regencor” said Tom Okarma, Executive Chairman, and co-founder. “We are pleased that we have sufficiently matured as a company to attract a senior executive with Sean's proven track record. He has held multiple senior executive positions in biopharma and has experience managing finance, corporate development, operations, product development and large clinical trials. We are all excited to start working with Sean to accelerate Regencor's growth trajectory”.
“I'm excited to be joining Regencor at such a dynamic time” said
Sean Edwards, CEO. “Having worked across several
therapeutic areas during my career, I haven't seen many technologies that hold this much
promise. Regencor's technology
has the potential to be a tremendous leap forward in our ability to treat myocardial
infarction and heart failure.”
Over the course of his career, Mr. Edwards has raised over $200M in institutional financings and has negotiated the acquisition and license of technologies and intellectual property. Experienced in guiding drugs and devices through the FDA, Mr. Edwards has also led the commercial launch of national and international brands in the physician dispensed and OTC drug channels. Prior to his career in life sciences, he spent eight years as an attorney specializing in complex commercial litigation for national and international law firms.
Regencor is a privately held spin-out of Stanford University that
has received multiple awards from the National
Institutes of Health and the California Institute for Regenerative Medicine. Its lead
product is a first-in-class,
proprietary biologic that stimulates cardiac regeneration after myocardial infarction (heart
attack). The recombinant
protein drives the proliferation of heart muscle and vascular cells exclusively within the
infarct zone, resulting in a
substantial reduction in scar volume and the sustained clinical improvement of heart
function in large animals with and
without comorbidities. The specific parameters of functional improvement reduce the
incidence of Major Adverse Cardiac
Events (MACE), which are the traditional outcome measures in randomized clinical trials. The
therapeutic is administered
by non-invasive subcutaneous delivery and will be the world's first outpatient therapy to
restore heart function after
Regencor's pipeline includes pre-clinical stage products under development for cardiomyopathy-associated heart failure discovered with their whole proteome screening platform.
To learn more about Regencor, please visit Regencor.com